RxDoctor Payments DataLook up a doctor →

Joselito Cabaccan, MD

Endocrinology, Diabetes & Metabolism · San Jose, CANPI 1801813720

Payments from drug & device makers

$1,428,626in general payments, 2019–2025

Across 4,080 payments — averaging $350.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$566K
  • Novo Nordisk$314K
  • Bayer$161K
  • AstraZeneca$64K
  • Boehringer Ingelheim$58K
  • Sanofi-aventis U.S. LLC$53K
  • plus $212K from 54 others
$52,093in research payments, 2019–2025

Across 82 payments — averaging $635.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$36K
  • Novo Nordisk AS$16K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC1,264$566,134
Novo Nordisk718$314,101
Bayer207$161,012
AstraZeneca(2 entities)160$63,747
Boehringer Ingelheim166$58,389
Sanofi-aventis U.S. LLC137$52,787
Corcept Therapeutics85$40,252
Amgen(2 entities)233$35,724
Mannkind Corporation179$28,017
Ascendis Pharma Endocrinology Inc24$23,932
Dexcom, Inc.45$19,379
Merck62$15,667
Johnson & Johnson(2 entities)55$15,266
Sanofi4$7,043
IBSA Pharma Inc.59$5,565
Eli Lilly15$4,541
Regeneron Healthcare Solutions, Inc.16$3,106
Xeris Pharmaceuticals, Inc.86$1,999
Novo Nordisk AS2$1,460
Radius Health, Inc.71$1,178
AbbVie49$996
Amarin Pharma, Inc.67$921
Abbott55$889
GSK50$657
Tandem Diabetes Care, Inc.23$567
Pfizer30$563
Kowa Pharmaceuticals America, Inc.20$374
Recordati_rare_diseases_inc.18$358
Ascensia Diabetes Care US Inc.12$356
Madrigal Pharmaceuticals9$338
Aurinia Pharma U.S., Inc.12$308
BETA Bionics, Inc.5$228
Esperion Therapeutics, Inc.12$203
Zealand Pharma US, Inc.11$173
Almatica Pharma LLC7$146
Shire North American Group Inc9$143
Antares Pharma, Inc.9$138
Ultragenyx Pharmaceutical Inc.7$133
Verity Pharmaceuticals Inc.7$125
Novartis6$120
Sequel Med Tech, LLC2$119
Arbor Pharmaceuticals, Inc.6$113
Embecta Corp.5$109
Senseonics, Incorporated5$101
Eisai Inc.4$94
Kyowa Kirin, Inc.4$91
Sanofi Pasteur Inc.3$72
Medtronic(2 entities)5$69
Averitas Pharma Inc.2$68
Insulet Corporation4$67
Neurocrine Biosciences, Inc.3$65
Boston Scientific2$48
Chiesi USA, Inc.2$45
Sun Pharmaceutical Industries Inc.2$40
Tolmar Pharmaceuticals, Inc.2$39
Organon1$32
Ascend Therapeutics US, LLC2$32
Biohaven Pharmaceutical Holding Company Ltd.2$30
Strongbridge US Inc.2$30
Amryt Pharma Holdings Ltd1$30

How this compares

$1,428,626 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California →

Medicare billing

Part B allowed, 2024
$2,390,992
Medicare patients
2,206
Services billed
112,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in San Jose

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →